Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021029238 - AGENT FOR PREVENTING OR TREATING TH17 CELL-INDUCED DISEASE AND SCREENING METHOD FOR AGENTS FOR PREVENTING OR TREATING TH17 CELL-INDUCED DISEASE

Publication Number WO/2021/029238
Publication Date 18.02.2021
International Application No. PCT/JP2020/029535
International Filing Date 31.07.2020
IPC
A61K 45/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61P 1/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 11/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
Applicants
  • 学校法人東京理科大学 TOKYO UNIVERSITY OF SCIENCE FOUNDATION [JP]/[JP]
Inventors
  • 岩倉 洋一郎 IWAKURA Yoichiro
  • 村山 正承 MURAYAMA Masanori
  • 小野 貴裕 ONO Takahiro
  • 松岡 眞子 MATSUOKA Mako
Agents
  • 正林 真之 SHOBAYASHI Masayuki
  • 岸武 弘樹 KISHITAKE Hiroki
Priority Data
2019-14805409.08.2019JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) AGENT FOR PREVENTING OR TREATING TH17 CELL-INDUCED DISEASE AND SCREENING METHOD FOR AGENTS FOR PREVENTING OR TREATING TH17 CELL-INDUCED DISEASE
(FR) AGENT DE PRÉVENTION OU DE TRAITEMENT DES MALADIES INDUITES PAR LES CELLULES TH17 ET MÉTHODE DE CRIBLAGE D'AGENTS DESTINÉS À PRÉVENIR OU À TRAITER DES MALADIES INDUITES PAR LES CELLULES TH17
(JA) Th17細胞誘導性疾患の予防又は治療剤、及びTh17細胞誘導性疾患の予防又は治療剤のスクリーニング方法
Abstract
(EN)
Provided are: an agent for preventing or treating Th17 cell-induced disease, the agent containing as an active ingredient an agonist that exhibits agonist activity against adiponectin receptors 2 (PAQR2) without exhibiting agonist activity against adiponectin receptors 1 (PAQR1); and a screening method for agents that prevent or treat Th17 cell-induced disease, the method including screening candidate agonists that exhibit agonist activity against adiponectin receptors 2 (PAQR2) without exhibiting agonist activity against adiponectin receptors 1 (PAQR1).
(FR)
L'invention concerne : un agent qui permet de prévenir ou de traiter des maladies induites par les cellules Th17, l'agent contenant en tant que principe actif un agoniste qui présente une activité agoniste envers les récepteurs de l'adiponectine de type 2 (PAQR2) sans présenter d'activité agoniste envers les récepteurs de l'adiponectine de type 1 (PAQR1) ; une méthode de criblage d'agents capable de prévenir ou de traiter des maladies induites par les cellules Th17, la méthode comprenant le criblage d'agonistes candidats qui présentent une activité agoniste envers les récepteurs de l'adiponectine de type 2 (PAQR2) sans présenter d'activité agoniste envers les récepteurs de l'adiponectine de type 1 (PAQR1).
(JA)
アディポネクチン受容体1(PAQR1)に対するアゴニスト活性を示さず、且つ、アディポネクチン受容体2(PAQR2)に対するアゴニスト活性を示すアゴニストを有効成分として含有するTh17細胞誘導性疾患の予防又は治療剤、並びに、アディポネクチン受容体1(PAQR1)に対するアゴニスト活性を示さず、且つ、アディポネクチン受容体2(PAQR2)に対するアゴニスト活性を示す候補アゴニストをスクリーニングすることを含むTh17細胞誘導性疾患の予防又は治療剤のスクリーニング方法を提供する。
Latest bibliographic data on file with the International Bureau